Press Releases

SOUTH SAN FRANCISCO, Calif. , July 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from July 13, 2021 , through July 27, 2021 , the Compensation

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY to host conference call on July 27, 2021 , at 8:00 a.m. PT ( 11:00 a.m. ET ) SOUTH SAN FRANCISCO, Calif.

Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325 advances to Phase 2a study in DME patients as a potential alternative to anti-VEGF therapies UNITY to host

SOUTH SAN FRANCISCO, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from May 18, 2021 through June 1, 2021 , the Compensation Committee of

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity -  Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022 -  Cash balance sufficient to fund operations into

UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif. , May 01, 2021 (GLOBE NEWSWIRE) -- UNITY

SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association

SOUTH SAN FRANCISCO, Calif. , April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from April 6, 2021 through April 20, 2021 , the Compensation Committee

SOUTH SAN FRANCISCO, Calif. , March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2020

SOUTH SAN FRANCISCO, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has officially joined UNITY as general counsel, and